Parvovirus B19-associated transient red cell aplasia in children: The role of bone marrow examination in unusual presentations

Pediatric Hematology and Oncology

Volumn 21, Issue 6, 2004, Pages 503-509

  Garewal, G ^a   Ahluwalia, J ^a   Das, R ^a   Marwaha, R K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Parvovirus B19; Pediatric; Transient aplastic crisis

Indexed keywords

ANTIANEMIC AGENT; IMMUNOGLOBULIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTHRALGIA; ARTICLE; BONE MARROW EXAMINATION; CASE REPORT; CHILD; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE DURATION; ERYTHEMA INFECTIOSUM; ERYTHROCYTE APLASIA; ERYTHROCYTE TRANSFUSION; FEVER; HEMOLYTIC ANEMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; MALE; PARVOVIRUS; SERODIAGNOSIS;

EID: 4444367523     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010490477293     Document Type: Article

References (19)

1. Young NS. Parvoviruses. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology, ed 3. Philadelphia: Lippincott-Raven; 1996:2199-2220.
2. Pattison JR, Jones SE, Hodgson J, Davis LR, White JM, Stroud CE. Parvovirus infection and hypoplastic crisis in sickle cell anaemia. Lancet. 1981;1:664-665.
3. Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type I (HIV-1): a treatable cause of anemia in AIDS. Ann Int Med. 1990;113:926-933.
4. Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol. 1998;25:151-153.
5. Kelly HA, Siebert D, Hammond R, Leydon J, Kiely P, Maskill W. The age specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiol Infect. 2000;124:449-457.
6. Tolvenstam T, Enbom M, Ghebrekidan H, et al. Seroprevalence of viral childhood infections in Eritrea. J Clin Virol. 2000;16:49-54.
7. Abraham M, Rudraraju R, Kannangai R, George K, Cherian T, Daniel D. A pilot study on the sero prevalence of parvovirus B19 infection. Indian J Med Res. 2002;115:139-143.
8. Marey AL, Fleming KA. Immunophenotyping of fetal haemopoietic cells permissive for human parvovirus B19 replication in vitro. Br J Haematol. 1992;82:302-309.
9. Frickhofen N, Chen ZJ, Young NS, Cohen B, Heimpel H, Abkowitz JL. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol. 1994;87:818-824.
10. Koduri PR. Novel cytomorphology of the giant proerythroblasts of parvovirus B19 infection. Am J Hematol. 1998;58:95-99.
11. Lefrere JJ, Bourgeois H. Human parvovirus associated with erythroblastopenia in iron deficiency anaemia (letter). J Clin Pathol. 1986;39:1277-1278.
12. Tarantino MD, Shahidi N. Pure red cell aplasia associated with parvovirus B19 (PB19) infection in iron deficiency. Pediatr Res. 1991;29:896A.
13. Sarode R, Garewal G, Marwaha N, et al. Pancytopenia in megaloblastic anemia - a study from North-West India. Trop Geogr Med. 1989;41:331-337.
14. Koch WC, Masey G, Russel CE, Adler SP. Manifestations and treatment of human parvovirus B19 infection in immunocompromized patients. J Pediatr. 1990;16:355-359.
15. Smith TJ, Cullen CW, Peck SD, Brown KE, Young NS. Pancytopenia secondary to parvovirus B19 infection in a child with acute lymphoblastic leukemia, mimicking leukemic relapse. Am J Hematol. 1995;50:226-227.
16. Broliden K, Tolfvenstam T, Ohlsson S, Henter JI. Persistent B19 parvovirus infection in pediatric malignancies. Med Pediatr Oncol. 1998;31:66-72.
17. Heegard ED, Jensen L, Hornsleth A, Schmiegelow K. The role of parvovirus B19 infection in acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1999;16:329-334.
18. McNall RY, Head DR, Pui CH, Razzouk BI. Parvovirus B19 infection in a child with acute lymphoblastic leukemia during induction therapy. J Pediatr Haematol Oncol. 2001;23:309-311.
19. Kurtzman GJ, Frickhofen N, Jenkins DW, Nienhuis AW, Young NS. Pure red cell aplasia of 10 years duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med. 1989;321:519-523.